CYPH Key Statistics, Chart & Performance
The current stock price of CYPH is 1.19 USD. In the past month the price increased by 7.21%.
CYPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About CYPH
Company Profile
Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2017-01-24. The firm focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
Company Info
CYPHERPUNK TECHNOLOGIES INC
47 Thorndike Street, Suite B1-1
Cambridge MASSACHUSETTS US
Employees: 52
Phone: 16172524343
CYPHERPUNK TECHNOLOGIES INC / CYPH FAQ
What does CYPH do?
Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2017-01-24. The firm focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
Can you provide the latest stock price for CYPHERPUNK TECHNOLOGIES INC?
The current stock price of CYPH is 1.19 USD. The price increased by 4.39% in the last trading session.
Does CYPHERPUNK TECHNOLOGIES INC pay dividends?
CYPH does not pay a dividend.
How is the ChartMill rating for CYPHERPUNK TECHNOLOGIES INC?
CYPH has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists CYPH stock?
CYPH stock is listed on the Nasdaq exchange.
What sector and industry does CYPHERPUNK TECHNOLOGIES INC belong to?
CYPHERPUNK TECHNOLOGIES INC (CYPH) operates in the Health Care sector and the Biotechnology industry.
How many employees does CYPHERPUNK TECHNOLOGIES INC have?
CYPHERPUNK TECHNOLOGIES INC (CYPH) currently has 52 employees.
CYPH Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CYPH.
CYPH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CYPH. The financial health of CYPH is average, but there are quite some concerns on its profitability.
CYPH Financial Highlights
Over the last trailing twelve months CYPH reported a non-GAAP Earnings per Share(EPS) of -1.22. The EPS increased by 36.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -445.76% | ||
| ROE | -1885.42% | ||
| Debt/Equity | 0 |